Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (1121) 1121
life sciences & biomedicine (1000) 1000
animals (982) 982
humans (902) 902
male (582) 582
phospholipase a2 (520) 520
phospholipase (427) 427
biological and medical sciences (393) 393
female (393) 393
phospholipases (387) 387
mice (379) 379
inflammation (327) 327
medical sciences (325) 325
phospholipases a2 (311) 311
rats (285) 285
lipids (272) 272
proteins (260) 260
enzymes (233) 233
pharmacology & pharmacy (218) 218
arachidonic acid (211) 211
phospholipase a (207) 207
middle aged (189) 189
phospholipases a - antagonists & inhibitors (188) 188
research (186) 186
medicine (185) 185
cell biology (177) 177
biochemistry & molecular biology (172) 172
research article (172) 172
phospholipases a - metabolism (170) 170
neurosciences (164) 164
signal transduction (163) 163
enzyme inhibitors - pharmacology (160) 160
phospholipases a2 - metabolism (160) 160
physiological aspects (153) 153
venom (153) 153
rodents (151) 151
disease models, animal (148) 148
adult (143) 143
pharmacology. drug treatments (142) 142
aged (140) 140
analysis (137) 137
immunology (135) 135
atherosclerosis (133) 133
kinases (133) 133
health aspects (130) 130
neurosciences & neurology (128) 128
gene expression (124) 124
science (123) 123
cells, cultured (122) 122
dose-response relationship, drug (122) 122
toxicology (119) 119
arachidonic acid - metabolism (114) 114
science & technology - other topics (114) 114
multidisciplinary sciences (113) 113
risk factors (111) 111
neurology (108) 108
abridged index medicus (105) 105
apoptosis (103) 103
care and treatment (102) 102
rats, sprague-dawley (102) 102
fundamental and applied biological sciences. psychology (101) 101
enzyme inhibitors - therapeutic use (100) 100
phosphorylation (100) 100
signal transduction - drug effects (100) 100
phospholipids (99) 99
cardiovascular system & cardiology (96) 96
cytokines (96) 96
biochemistry (95) 95
mice, inbred c57bl (93) 93
physiology (93) 93
studies (93) 93
biomedicine (89) 89
fatty acids (89) 89
time factors (88) 88
calcium - metabolism (86) 86
biology (84) 84
calcium (83) 83
oxidative stress (82) 82
snakes (82) 82
phospholipase c (81) 81
rats, wistar (81) 81
biomarkers (80) 80
chemistry (80) 80
cardiovascular disease (79) 79
biomarkers - blood (77) 77
cell line (77) 77
cholesterol (77) 77
metabolism (76) 76
cardiac & cardiovascular systems (75) 75
medicine & public health (75) 75
treatment outcome (75) 75
life sciences (74) 74
oncology (74) 74
review (74) 74
cell line, tumor (68) 68
lipoproteins (68) 68
pharmacology (68) 68
medicine, research & experimental (67) 67
research & experimental medicine (67) 67
in vitro techniques (66) 66
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1986) 1986
Japanese (12) 12
German (11) 11
Portuguese (10) 10
Russian (5) 5
Chinese (3) 3
French (2) 2
Italian (2) 2
Spanish (2) 2
Danish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Phospholipase A2 enzymes and the risk of atherosclerosis
by Rosenson, Robert S and Hurt-Camejo, Eva
European heart journal, ISSN 0195-668X, 12/2012, Volume 33, Issue 23, pp. 2899 - 2909
Lipoprotein-associated phospholipase A | Secretory phospholipase A | Cardiovascular disease | Darapladib | Varespladib | Humans | Oximes - therapeutic use | Cardiovascular Diseases - enzymology | Mutation, Missense - genetics | Myocytes, Cardiac - enzymology | Atherosclerosis - enzymology | Phospholipases A2, Secretory - chemistry | 1-Alkyl-2-acetylglycerophosphocholine Esterase - antagonists & inhibitors | Indoles - pharmacology | Acetates - therapeutic use | Benzaldehydes - therapeutic use | 1-Alkyl-2-acetylglycerophosphocholine Esterase - chemistry | Biomarkers - metabolism | Atherosclerosis - drug therapy | Guinea Pigs | Risk Factors | Enzyme Inhibitors - pharmacology | Benzaldehydes - pharmacology | Clinical Trials as Topic | Myocardial Ischemia - enzymology | Phospholipases A2, Secretory - physiology | Enzyme Inhibitors - therapeutic use | Animals | Phospholipases A2, Secretory - antagonists & inhibitors | Oximes - pharmacology | Indoles - therapeutic use | Polymorphism, Genetic - genetics | Acetates - pharmacology | Mice | 1-Alkyl-2-acetylglycerophosphocholine Esterase - physiology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Phospholipase A2 inhibitors
by Serruys, Patrick W and Garcia-Garcia, Hector M
Current opinion in lipidology, ISSN 0957-9672, 08/2009, Volume 20, Issue 4, pp. 327 - 332
Inflammation | Phospholipase A2 | Darapladib | Atherosclerosis | Varespladib | Animals | Atherosclerosis - drug therapy | Inflammation - drug therapy | Humans | 1-Alkyl-2-acetylglycerophosphocholine Esterase - antagonists & inhibitors | Oximes - therapeutic use | Indoles - therapeutic use | Acetates - therapeutic use | Benzaldehydes - therapeutic use | Blood Proteins - therapeutic use | Atherosclerosis - metabolism | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Role of Lipoprotein-Associated Phospholipase A2 in Atherosclerosis: Biology, Epidemiology, and Possible Therapeutic Target
by Zalewski, Andrew and Macphee, Colin
Arteriosclerosis, thrombosis, and vascular biology, ISSN 1079-5642, 05/2005, Volume 25, Issue 5, pp. 923 - 931
Lipoprotein-associated phospholipase A | Inflammation | Atherosclerosis | Cardiovascular system | Cardiology. Vascular system | Miscellaneous | Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous | Atherosclerosis (general aspects, experimental research) | Pharmacology. Drug treatments | Biological and medical sciences | Medical sciences | Blood and lymphatic vessels | Vasculitis - metabolism | Atherosclerosis - drug therapy | Vasculitis - epidemiology | Humans | Risk Factors | Phospholipases A - immunology | Phospholipases A2 | Atherosclerosis - epidemiology | Enzyme Inhibitors - therapeutic use | Atherosclerosis - metabolism | Blood Vessels - immunology | Animals | Phospholipases A - genetics | Vasculitis - drug therapy | 1-Alkyl-2-acetylglycerophosphocholine Esterase | Phospholipases A - antagonists & inhibitors | Blood Vessels - enzymology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Inhibitors of Brain Phospholipase A2 Activity: Their Neuropharmacological Effects and Therapeutic Importance for the Treatment of Neurologic Disorders
by Akhlaq A. Farooqui and Wei-Yi Ong and Lloyd A. Horrocks
Pharmacological reviews, ISSN 0031-6997, 09/2006, Volume 58, Issue 3, pp. 591 - 620
Nervous System Diseases - enzymology | Pain - prevention & control | Humans | Brain Injuries - chemically induced | Nervous System Diseases - drug therapy | Brain - enzymology | Blood Proteins - therapeutic use | Phospholipases A - metabolism | Phospholipases A2 | Kainic Acid - adverse effects | Blood Proteins - pharmacology | Brain Injuries - prevention & control | Animals | Models, Biological | Pain - drug therapy | Blood Proteins - physiology | Brain Injuries - rehabilitation | Neurons - drug effects | Phospholipases A - physiology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Phospholipase A2 superfamily members play divergent roles after spinal cord injury
by López‐Vales, Rubèn and Ghasemlou, Nader and Redensek, Adriana and Kerr, Bradley J and Barbayianni, Efrosini and Antonopoulou, Georgia and Baskakis, Constantinos and Rathore, Khizr I and Constantinou‐Kokotou, Violetta and Stephens, Daren and Shimizu, Takao and Dennis, Edward A and Kokotos, George and David, Samuel
The FASEB journal, ISSN 0892-6638, 12/2011, Volume 25, Issue 12, pp. 4240 - 4252
secondary damage | Key Words | CNS injury | lipid metabolism | prostaglandin receptors | Prostaglandin receptors | Lipid metabolism | Secondary damage | Group IV Phospholipases A2 - genetics | Group VI Phospholipases A2 - deficiency | Spinal Cord Injuries - drug therapy | Group IV Phospholipases A2 - antagonists & inhibitors | Group II Phospholipases A2 - antagonists & inhibitors | Group II Phospholipases A2 - metabolism | Group VI Phospholipases A2 - metabolism | Spinal Cord Injuries - pathology | Group IV Phospholipases A2 - metabolism | Group VI Phospholipases A2 - antagonists & inhibitors | Spinal Cord Injuries - enzymology | Group II Phospholipases A2 - deficiency | Enzyme Inhibitors - chemistry | Female | Phospholipase A2 Inhibitors | Group IV Phospholipases A2 - deficiency | Locomotion - drug effects | Receptor Cross-Talk | Phospholipases A2 - metabolism | Enzyme Inhibitors - therapeutic use | Receptors, Prostaglandin E, EP1 Subtype - metabolism | Mice, Knockout | Phospholipases A2 - deficiency | Animals | Phospholipases A2 - classification | Mice | Mice, Inbred BALB C | Spinal Cord Injuries - physiopathology | Locomotion - physiology | Index Medicus | Research Communications
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Phospholipase A2 inhibitors for the treatment of inflammatory diseases: a patent review (2010 - present)
by Magrioti, Victoria and Kokotos, George
Expert opinion on therapeutic patents, ISSN 1354-3776, 03/2013, Volume 23, Issue 3, pp. 333 - 344
atherosclerosis | inhibitors | phospholipase A | arthritis | inflammation | multiple sclerosis | cancer | Multiple sclerosis | Inhibitors | Phospholipase A2 | Atherosclerosis | Arthritis | Inflammation | Cancer | Animals | Calcium - physiology | Anti-Inflammatory Agents - pharmacology | Inflammation - drug therapy | Humans | Receptors, Phospholipase A2 - antagonists & inhibitors | Anti-Inflammatory Agents - therapeutic use | Cytosol - metabolism | Phospholipases A2 - metabolism | Lipoproteins - physiology | Receptors, Phospholipase A2 - metabolism | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Blockade of cytosolic phospholipase A2 α prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses
by Marusic, Suzana and Thakker, Paresh and Pelker, Jeffrey W and Stedman, Nancy L and Lee, Katherine L and McKew, John C and Han, Lixin and Xu, Xin and Wolf, Stan F and Borey, Adam J and Cui, Junqing and Shen, Marina W.H and Donahue, Fran and Hassan-Zahraee, Mina and Leach, Michael W and Shimizu, Takao and Clark, James D
Journal of neuroimmunology, ISSN 0165-5728, 2008, Volume 204, Issue 1, pp. 29 - 37
Neurology | Allergy and Immunology | α | 5-LO | EAE | cPLA | Th1 | Th17 | COX-1/2 | Hydroxyurea - analogs & derivatives | Hydroxyurea - pharmacology | Peptide Fragments | Th1 Cells - physiology | Benzoates - therapeutic use | Group IV Phospholipases A2 - antagonists & inhibitors | Naproxen - pharmacology | Encephalomyelitis, Autoimmune, Experimental - chemically induced | Time Factors | Female | Disease Models, Animal | Severity of Illness Index | Th1 Cells - drug effects | Encephalomyelitis, Autoimmune, Experimental - physiopathology | Cytokines - metabolism | Mice, Inbred C57BL | Cells, Cultured | Enzyme Inhibitors - pharmacology | Lipoxygenase Inhibitors - therapeutic use | Myelin-Oligodendrocyte Glycoprotein | Glycoproteins | Sulfonamides - pharmacology | Enzyme Inhibitors - therapeutic use | Naproxen - therapeutic use | Cyclooxygenase Inhibitors - pharmacology | Animals | Encephalomyelitis, Autoimmune, Experimental - enzymology | Analysis of Variance | Sulfonamides - therapeutic use | Seveso Accidental Release | Benzoates - pharmacology | Encephalomyelitis, Autoimmune, Experimental - prevention & control | Hydroxyurea - therapeutic use | Mice, Inbred NOD | Cell Proliferation - drug effects | Mice | Lipoxygenase Inhibitors - pharmacology | Cyclooxygenase Inhibitors - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Anti-inflammatory therapies for cardiovascular disease
by Ridker, Paul M and Lüscher, Thomas F
European heart journal, ISSN 0195-668X, 07/2014, Volume 35, Issue 27, pp. 1782 - 1791
Darapladib | Atherosclerosis | Inflammasome | Inflammation | Colchicine | Salsalate | C reactive protein | Canakinumab | Methotrexate | Interleukin-6 | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Hydroxychloroquine - therapeutic use | Interleukin-6 - antagonists & inhibitors | NLR Family, Pyrin Domain-Containing 3 Protein | Colchicine - therapeutic use | Humans | Cell Adhesion Molecules - antagonists & inhibitors | Methotrexate - therapeutic use | Sirtuins - therapeutic use | Vaccination - methods | Lipoproteins, HDL - drug effects | Interleukin-1 - physiology | Interleukin-6 - physiology | Anti-Inflammatory Agents - therapeutic use | Interleukin-1 - antagonists & inhibitors | Leukotriene Antagonists - therapeutic use | Carrier Proteins - physiology | Adaptive Immunity - physiology | Phospholipase A2 Inhibitors - therapeutic use | Atherosclerosis - drug therapy | Serpins - therapeutic use | C-Reactive Protein - physiology | Antioxidants - therapeutic use | Tumor Necrosis Factor-alpha - drug effects | Signal Transduction - drug effects | Tumor Necrosis Factor-alpha - physiology | Thrombosis - drug therapy | Receptors, Interleukin-1 - antagonists & inhibitors | Index Medicus | Review
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Phospholipase A2 inhibitors in atherosclerosis: the race is on
by Corson, Marshall A
The Lancet (British edition), ISSN 0140-6736, 2009, Volume 373, Issue 9664, pp. 608 - 610
Internal Medicine | Enzyme Inhibitors - adverse effects | Coronary Disease - blood | Phospholipases A2, Secretory - classification | Heptanoic Acids - therapeutic use | Humans | Phospholipases A2, Secretory - blood | Oximes - therapeutic use | Coronary Artery Disease - drug therapy | Coronary Artery Disease - blood | Enzyme Inhibitors - therapeutic use | Atorvastatin Calcium | Coronary Disease - enzymology | Phospholipases A2, Secretory - antagonists & inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Coronary Disease - drug therapy | Cholesterol, LDL - blood | Benzaldehydes - therapeutic use | Pyrroles - therapeutic use | Clinical Trials, Phase II as Topic | Inhibitor drugs | Clinical trials | Cardiovascular disease | Acute coronary syndromes | Cholesterol | Risk factors | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Potent and Selective Fluoroketone Inhibitors of Group VIA Calcium-Independent Phospholipase A2
by Kokotos, George and Hsu, Yuan-Hao and Burke, John E and Baskakis, Constantinos and Kokotos, Christoforos G and Magrioti, Victoria and Dennis, Edward A
Journal of medicinal chemistry, ISSN 0022-2623, 05/2010, Volume 53, Issue 9, pp. 3602 - 3610
Ketones - pharmacology | Cell Line | Phospholipases A2, Calcium-Independent - antagonists & inhibitors | Group VI Phospholipases A2 - antagonists & inhibitors | Fluorine | Enzyme Inhibitors - chemistry | Humans | Ketones - therapeutic use | Structure-Activity Relationship | Drug Evaluation, Preclinical | Naphthalenes - therapeutic use | Naphthalenes - pharmacology | Index Medicus | inhibitors | polyfluoro ketones | heptafluoropropyl ketones | phospholipase A2
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Inhibitors of secretory phospholipase A2 group IIA
by Reid, Robert C
Current medicinal chemistry, ISSN 0929-8673, 2005, Volume 12, Issue 25, pp. 3011 - 3026
inhibitor | PLA | sPLA | Clinical trial | Inflammation | Anti-inflammatory | Phospholipase A | Secretory PLA | Pharmacology & Pharmacy | Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Chemistry, Medicinal | Science & Technology | Humans | Enzyme Inhibitors - pharmacology | Inflammation - immunology | Structure-Activity Relationship | Phospholipases A2 | Enzyme Inhibitors - therapeutic use | Group II Phospholipases A2 | Animals | Inflammation - drug therapy | Phospholipases A - antagonists & inhibitors | Molecular Structure | Clinical Trials, Phase II as Topic | Disease Models, Animal
Journal Article
Details down arrow
12. Full Text Inhibitors of phospholipase A2 and their therapeutic potential: an update on patents (2012-2016)
by Kokotou, Maroula G and Limnios, Dimitris and Nikolaou, Aikaterini and Psarra, Anastasia and Kokotos, George
Expert opinion on therapeutic patents, ISSN 1354-3776, 02/2017, Volume 27, Issue 2, pp. 217 - 225
atherosclerosis | autoimmune diseases | inhibitors | phospholipase A | inflammation | Arthritis | cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Differing roles for members of the phospholipase A2 superfamily in experimental autoimmune encephalomyelitis
by Kalyvas, Athena and Baskakis, Constantinos and Magrioti, Victoria and Constantinou-Kokotou, Violetta and Stephens, Daren and López-Vales, Rubèn and Lu, Jian-Qiang and Yong, V. Wee and Dennis, Edward A and Kokotos, George and David, Samuel
Brain (London, England : 1878), ISSN 0006-8950, 5/2009, Volume 132, Issue 5, pp. 1221 - 1235
EAE | Multiple sclerosis | Cytokines | Fatty acids | Phospholipase A | Chemokines | Immunohistochemistry | T-Lymphocytes - enzymology | Humans | RNA, Messenger - analysis | Male | Young Adult | Flow Cytometry | Protein Isoforms - chemistry | Adult | Female | Ketones - therapeutic use | Encephalomyelitis, Autoimmune, Experimental - genetics | Phospholipases A2 - physiology | Phospholipase A2 Inhibitors | Cytokines - immunology | Phospholipases A2 - chemistry | Gene Expression | Multiple Sclerosis - enzymology | Encephalomyelitis, Autoimmune, Experimental - drug therapy | Mice, Inbred C57BL | Spinal Cord - enzymology | Fatty Acids - analysis | Multiple Sclerosis - genetics | Amides - therapeutic use | Enzyme Inhibitors - therapeutic use | Disease Progression | Protein Isoforms - physiology | Macrophages - enzymology | Animals | Encephalomyelitis, Autoimmune, Experimental - enzymology | Fluorescent Antibody Technique | Mice | Protein Isoforms - antagonists & inhibitors | Index Medicus | Abridged Index Medicus | Phospholipase A2 | fatty acids | multiple sclerosis | cytokines | chemokines | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Phospholipase A2 inhibitors as potential anti-inflammatory agents
by Meyer, M.C and Rastogi, P and Beckett, C.S and McHowat, Jane
Current pharmaceutical design, ISSN 1381-6128, 2005, Volume 11, Issue 10, pp. 1301 - 1312
Animals | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Humans | Phospholipases A - antagonists & inhibitors | Blood Proteins - therapeutic use | Phospholipases A - metabolism | Phospholipases A2 | Anti-Inflammatory Ag